ABBOTT PARK, Ill., June 14, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON® (pancrelipase) ...
VIENNA, Austria — The appropriate dose of pancreatic enzyme replacement therapy (PERT) for exocrine pancreatic insufficiency (EPI) depends on the root cause of the insufficiency, according to results ...
Enzyme replacement for Gaucher disease (GD) has now been available for 17 years. This therapy, the first enzyme preparation developed for the treatment of a lysosomal storage disorder, has ...
Degenerative joint changes have been reported in human mucopolysaccharidosis VI (MPS VI) and are a prominent feature of feline MPS VI. Joint disease has proven refractory to intravenous enzyme ...
A look at the formulation challenges in pancreatic enzyme products. Specialty pharmaceuticals are an important component of the pharmaceutical market. They are broadly defined as drugs that target a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback